Consistent with the weight-reducing profile of GLP-1 receptor agonists, efpeglenatide, developed for weight reduction in individuals with obesity, has been shown to induce weight loss of approximately 6%–7% in patients with T2DM (Gerstein et al., 2021). This evidence concerns the gene GLP1R and obesity disorder.